

VINSON & ELKINS L.L.P.
2300 FIRST CITY TOWER
1001 FANNIN STREET
HOUSTON, TEXAS 77002-6760
TELEPHONE (713) 758-2222
FAX (713) 758-2346
www.velaw.com

Stephen M. Hash
Direct Dial 512/542-8504
Direct Fax 512/236-3278
shash@velaw.com

March 25, 2004

MAIL STOP DD

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

I, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450:

March 25, 2004
Date

Stephen M. Hash

Re: U. S. Patent Application Serial No. 10/670,135 entitled "ENDOGENOUS GRANZYME B IN HUMAN NON-HEMATOPOIETIC CELLS" by Hong-Ji Xu, et al. (Our Ref: AND541/4-007US/58011)

Dear Sirs:

Enclosed for filing in the above-referenced patent application are the following:

1. Information Disclosure Statement;
2. Form SB08 along with references C1-C40; and
3. A return postcard to acknowledge receipt of these documents. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Assistant Commissioner is hereby authorized to deduct said fees from VINSON & ELKINS L.L.P. Deposit Account No. 22-0365/AND541/4-007US/58011.

Respectfully submitted,

Stephen M. Hash
Reg. No. 45,490

1891:3058
Enclosures



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Xu, et al.

Serial No.: 10/670,135

Filed: September 24, 2003

For: ENDOGENOUS GRANZYME B IN NON-
IMMUNE CELLS

Group Art Unit: 1651

Examiner: Unknown

Atty. Dkt. No.: AND541/4-007US/58011

CERTIFICATE OF MAILING

I, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450:

March 25, 2004

Date


Stephen M. Hash

INFORMATION DISCLOSURE STATEMENT

MAIL STOP DD

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on the attached Form SB/08/B be considered by the Examiner and made of record. Copies of the listed documents (References C1-C40) required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Vinson & Elkins L.L.P. Deposit Account No. 22-0365/AND541/4-007US/58011.

Respectfully submitted,


A handwritten signature in black ink, appearing to read 'S. Hash', with a long, sweeping horizontal stroke extending to the right.


Stephen M. Hash
Reg. No. 45,490
Attorney for Applicant


Vinson & Elkins L.L.P.
2300 First City Tower
1001 Fannin Street
Houston, Texas 77002-6760
512/542-8504

Date: March 25, 2004

434614_1.DOC

INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		Application Number		10/670,135				
		Filing Date		09/24/03				
		First Named Inventor		Hong-Ji Xu				
		Group Art Unit		1651				
		Examiner Name		Unknown				
Sheet	5	of	3	Attorney Docket Number		AND541/4-007US/58011		
NON-PATENT LITERATURE DOCUMENTS								
	C28	SCHMID, J., and WEISSMANN, C. (1987) Induction of mRNA for a serine protease and a β -thromboglobulin-like protein in mitogen-stimulated human leukocytes. <i>J. Immunol.</i> 139, 250-256.						
	C29	SHAN, B., et al. (1996). The molecular basis of E2F-1/DP-1-induced S-phase entry and apoptosis. <i>Cell Growth Differ.</i> 7, 689-697.						
	C30	SHI, L., et al. (1997). Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization. <i>J. Exp. Med.</i> 185, 855-866.						
	C31	SHRESTA, S., et al. (1997). Mechanisms responsible for granzyme B-independent cytotoxicity. <i>Blood</i> 89, 4085-4091.						
	C32	SUN, J., et al. (2001). Importance of the P4' residue in human granzyme B inhibitors and substrates revealed by scanning mutagenesis of the proteinase inhibitor 9 reactive center loop. <i>J. Biol. Chem.</i> 276, 15177-15184.						
	C33	TAN, X., et al. (1997). Degradation of retinoblastoma protein in tumor necrosis factor and CD95-induced cell death. <i>J. Biol. Chem.</i> 272, 9613-9616.						
	C34	TRAPANI, J. A., et al. (1996). Localization of granzyme B in the nucleus. A putative role in the mechanism of cytotoxic lymphocyte-mediated apoptosis. <i>J. Biol. Chem.</i> 271, 4127-4133.						
	C35	WARGNIER, A., et al. (1995). Identification of human granzyme B promoter regulatory elements interacting with activated T-cell-specific proteins: implication of Ikaros and CBF binding sites in promoter activation. <i>Proc. Natl. Acad. Sci. U. S. A.</i> 92, 6930-6934.						
	C36	XU, H. -J. (1995). Altered retinoblastoma (RB) protein expression in human malignancies. <i>Adv. Anat. Pathol.</i> 2, 213-226.						
	C37	XU, H.-J., et al. (1997). Reexpression of retinoblastoma protein induces tumor cell senescence and telomerase inhibition. <i>Oncogene</i> 15, 2589-2596.						
	C38	YANG, X., et al. (1998). Granzyme B mimics apical caspases. Description of a unified pathway for trans-activation of executioner caspase-3 and -7. <i>J. Biol. Chem.</i> 273, 34278-34283.						
	C39	YASUKAWA, M., et al. (2000). Granule exocytosis, and not the Fas/Fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4(+) as well as CD8(+) cytotoxic T lymphocytes in humans. <i>Blood</i> 95, 2352-2355.						
	C40	ZHOU, Y., et al. (1994). Further characterization of retinoblastoma gene-mediated cell growth and tumor suppression in human cancer cells. <i>Proc. Natl. Acad. Sci. U. S. A.</i> 91, 4165-4169.						
Examiner Signature					Date Considered			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		Application Number		10/670,135				
		Filing Date		09/24/03				
		First Named Inventor		Hong-Ji Xu				
		Group Art Unit		1651				
		Examiner Name		Unknown				
Sheet	1	of	3	Attorney Docket Number		AND541/4-007US/58011		
NON-PATENT LITERATURE DOCUMENTS								
	C1	AN, B., AND DOU, Q. P. (1996). Cleavage of retinoblastoma protein during apoptosis: an interleukin 1 beta-converting enzyme-like protease as candidate. <i>Cancer Res.</i> 56, 438-442.						
	C2	BABICHUK, C.K., DUGGAN, B.L., AND BLEACKLEY, R.C. (1996). In vivo regulation of murine granzyme B gene transcription in activated primary T cells. <i>J. Biol. Chem.</i> 271, 16485-16493.						
	C3	BERTHOU, C., et al. (1995). Granzyme B and perforin lytic proteins are expressed in CD34 ⁺ peripheral blood progenitor cells mobilized by chemotherapy and granulocyte colony-stimulating factor. <i>Blood</i> 86, 3500-3506.						
	C4	BERTHOU, C., et al. (1997). Acquisition of granzyme B and Fas ligand proteins by human keratinocytes contributes to epidermal cell defense. <i>J. Immunol.</i> 159, 5293-5300.						
	C5	BRUNO, A.P., et al. (2000). Acute myeloblastic leukemic cells acquire cellular cytotoxicity under genotoxic stress: implication of granzyme B and perforin. <i>Blood</i> 96, 1914-1920.						
	C6	CHEN, P.L., et al. (1992). Stability of retinoblastoma gene expression determines the tumorigenicity of reconstituted retinoblastoma cells. <i>Cell Growth Differ.</i> 3, 119-125.						
	C7	CHEN, W.D., et al. (1997). Apoptosis is associated with cleavage of a 5-kDa fragment from RB which mimics dephosphorylation and modulates E2F binding. <i>Oncogene</i> 14, 1243-1248.						
	C8	CORDON-CARDO, C., AND RICHON, V.M. (1994). Expression of the retinoblastoma protein is regulated in normal human tissues. <i>Am. J. Pathol.</i> 144, 500-510.						
	C9	DYSON, N. (1998). The regulation of E2F by pRB-family proteins. <i>Genes Dev.</i> 12: 2245-2262.						
	C10	FATTMAN, C.L., et al. (1998). p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifen-induced apoptosis in human breast carcinoma cells. <i>Cancer Letters</i> 130, 103-113.						
	C11	GRAUBERT, T.A., et al. (1997). Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. <i>J. Clin. Invest.</i> 100, 904-911.						
	C12	HAAS-KOGAN, D.A., et al. (1995). Inhibition of apoptosis by the retinoblastoma gene product. <i>EMBO J.</i> 14, 461-472.						
	C13	HEUSEL, J.W., et al. (1994). Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. <i>Cell</i> 76, 977-987.						
Examiner Signature					Date Considered			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		Application Number		10/670,135	
		Filing Date		09/24/03	
		First Named Inventor		Hong-Ji Xu	
		Group Art Unit		1651	
		Examiner Name		Unknown	
Sheet 1 of 3		Attorney Docket Number		AND541/4-007US/58011	
NON-PATENT LITERATURE DOCUMENTS					
	C14	HIRST, C.E., et al. Perforin-independent expression of granzyme B and proteinase inhibitor 9 in human testis and placenta suggests a role for granzyme B-mediated proteolysis in reproduction. <i>Molecular Human Reproduction</i> , 7:1133-1142, 2001.			
	C15	HOFMANN, F., et al. (1996). The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. <i>Genes Dev.</i> 10, 2949-2959.			
	C16	HU, SX, et al. (2003) Expression of endogenous granzyme B in a subset of human primary breast carcinomas. <i>Br. J. Can.</i> 89(1):135-9.			
	C17	HUANG, H.J., et al. (1988). Suppression of the neoplastic phenotype by replacement of the <i>RB</i> gene in human cancer cells. <i>Science</i> 242, 1563-1566.			
	C18	KENNEA, NL, and MEHMET, H.J (2002) Neural stem cells, <i>Pathol.</i> , 197(4):536-50.			
	C19	KLEIN, J.L., et al. (1989). Genomic organization and chromosomal assignment for a serine protease gene (CSPB) expressed by human cytotoxic lymphocytes. <i>Genomics</i> 5, 110-117.			
	C20	KONTANI, K., et al. (2001). Involvement of granzyme B and perforin in suppressing nodal metastasis of cancer cells in breast and lung cancers. <i>Eur. J. Surg. Oncol.</i> 27,180-186.			
	C21	KREK, W., et al. (1995). Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. <i>Cell</i> , 83: 1149-1158.			
	C22	LOBE, C.G., et al. (1986). Novel serine proteases encoded by two cytotoxic T lymphocyte-specific genes. <i>Science</i> 232, 858-861.			
	C23	MOTYKA, B., et al. (2000) Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. <i>Cell</i> 103, 491-500.			
	C24	OGURA, Y., et al. (2001). Apoptosis and allograft rejection in the absence of CD8 ⁺ T cells. <i>Transplantation</i> 71, 1827-1834.			
	C25	PINKOSKI, M. J., et al. (2000). Nuclear translocation of granzyme B in target cell apoptosis. <i>Cell Death Differ.</i> 7, 17-24.			
	C26	QIN, X.Q., et al. (1992). Identification of a growth suppression domain within the retinoblastoma gene product. <i>Genes Dev.</i> 6, 953-964.			
	C27	ROMANO, G., et al. (2000) Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications <i>Stem Cells</i> 18: 19-39.			
Examiner Signature				Date Considered	